Loading...

Prestige Consumer Healthcare

NYSE:PBH
Snowflake Description

Moderate growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PBH
NYSE
$2B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in North America, Australia, and internationally. The last earnings update was 69 days ago. More info.


Add to Portfolio Compare Print
PBH Share Price and Events
7 Day Returns
3.7%
NYSE:PBH
-0.9%
US Pharmaceuticals
-1.2%
US Market
1 Year Returns
-12.8%
NYSE:PBH
3.7%
US Pharmaceuticals
3.4%
US Market
PBH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Prestige Consumer Healthcare (PBH) 3.7% 2.9% 13.4% -12.8% -40.8% -0.5%
US Pharmaceuticals -0.9% -4% 0.8% 3.7% 0.2% 12.1%
US Market -1.2% 1.2% 1.7% 3.4% 35.5% 41.6%
1 Year Return vs Industry and Market
  • PBH underperformed the Pharmaceuticals industry which returned 3.7% over the past year.
  • PBH underperformed the Market in United States of America which returned 3.4% over the past year.
Price Volatility
PBH
Industry
5yr Volatility vs Market

PBH Value

 Is Prestige Consumer Healthcare undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Prestige Consumer Healthcare to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Prestige Consumer Healthcare.

NYSE:PBH Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.1%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NYSE:PBH
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.732 (1 + (1- 21%) (109.46%))
1.245
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.24
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.245 * 5.96%)
10.15%

Discounted Cash Flow Calculation for NYSE:PBH using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Prestige Consumer Healthcare is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NYSE:PBH DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.15%)
2020 200.54 Analyst x2 182.06
2021 203.53 Analyst x2 167.75
2022 207.25 Est @ 1.83% 155.07
2023 211.60 Est @ 2.1% 143.74
2024 216.44 Est @ 2.29% 133.48
2025 221.67 Est @ 2.42% 124.11
2026 227.24 Est @ 2.51% 115.51
2027 233.10 Est @ 2.58% 107.57
2028 239.22 Est @ 2.62% 100.22
2029 245.57 Est @ 2.66% 93.40
Present value of next 10 years cash flows $1,322.90
NYSE:PBH DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $245.57 × (1 + 2.73%) ÷ (10.15% – 2.73%)
$3,400.03
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $3,400.03 ÷ (1 + 10.15%)10
$1,293.14
NYSE:PBH Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,322.90 + $1,293.14
$2,616.04
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,616.04 / 51.20
$51.09
NYSE:PBH Discount to Share Price
Calculation Result
Value per share (USD) From above. $51.09
Current discount Discount to share price of $32.09
= -1 x ($32.09 - $51.09) / $51.09
37.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Prestige Consumer Healthcare is available for.
Intrinsic value
37%
Share price is $32.09 vs Future cash flow value of $51.09
Current Discount Checks
For Prestige Consumer Healthcare to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Prestige Consumer Healthcare's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Prestige Consumer Healthcare's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Prestige Consumer Healthcare's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Prestige Consumer Healthcare's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NYSE:PBH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.69
NYSE:PBH Share Price ** NYSE (2019-07-19) in USD $32.09
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 17.84x
United States of America Market PE Ratio Median Figure of 3,080 Publicly-Listed Companies 17.88x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Prestige Consumer Healthcare.

NYSE:PBH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:PBH Share Price ÷ EPS (both in USD)

= 32.09 ÷ -0.69

-46.67x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Prestige Consumer Healthcare is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Prestige Consumer Healthcare is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Prestige Consumer Healthcare's expected growth come at a high price?
Raw Data
NYSE:PBH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -46.67x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
80.6%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.7x
United States of America Market PEG Ratio Median Figure of 2,119 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Prestige Consumer Healthcare, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Prestige Consumer Healthcare's assets?
Raw Data
NYSE:PBH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $21.16
NYSE:PBH Share Price * NYSE (2019-07-19) in USD $32.09
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 186 Publicly-Listed Pharmaceuticals Companies 3.1x
United States of America Market PB Ratio Median Figure of 5,245 Publicly-Listed Companies 1.79x
NYSE:PBH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:PBH Share Price ÷ Book Value per Share (both in USD)

= 32.09 ÷ 21.16

1.52x

* Primary Listing of Prestige Consumer Healthcare.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Prestige Consumer Healthcare is good value based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Prestige Consumer Healthcare's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Prestige Consumer Healthcare has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PBH Future Performance

 How is Prestige Consumer Healthcare expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
80.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Prestige Consumer Healthcare expected to grow at an attractive rate?
  • Prestige Consumer Healthcare's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Prestige Consumer Healthcare's earnings growth is expected to exceed the United States of America market average.
  • Prestige Consumer Healthcare's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NYSE:PBH Future Growth Rates Data Sources
Data Point Source Value (per year)
NYSE:PBH Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 80.6%
NYSE:PBH Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts -0.6%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 16.2%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.2%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NYSE:PBH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NYSE:PBH Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-03-31 964 218 155 5
2020-03-31 955 214 147 5
NYSE:PBH Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 976 189 -36
2018-12-31 991 193 64
2018-09-30 1,020 197 340
2018-06-30 1,039 212 340
2018-03-31 1,041 210 340
2017-12-31 1,026 163 390
2017-09-30 972 156 107
2017-06-30 929 151 109
2017-03-31 882 149 69
2016-12-31 849 179 72
2016-09-30 833 185 69
2016-06-30 824 182 68

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Prestige Consumer Healthcare's earnings are expected to grow significantly at over 20% yearly.
  • Prestige Consumer Healthcare's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NYSE:PBH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Prestige Consumer Healthcare Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NYSE:PBH Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-03-31 2.95 2.99 2.89 4.00
2020-03-31 2.81 2.82 2.80 4.00
NYSE:PBH Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.69
2018-12-31 1.22
2018-09-30 6.46
2018-06-30 6.42
2018-03-31 6.40
2017-12-31 7.35
2017-09-30 2.02
2017-06-30 2.05
2017-03-31 1.31
2016-12-31 1.36
2016-09-30 1.30
2016-06-30 1.29

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Prestige Consumer Healthcare is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Prestige Consumer Healthcare's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Prestige Consumer Healthcare has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PBH Past Performance

  How has Prestige Consumer Healthcare performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Prestige Consumer Healthcare's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Prestige Consumer Healthcare does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Prestige Consumer Healthcare's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Prestige Consumer Healthcare's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Prestige Consumer Healthcare's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Prestige Consumer Healthcare Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NYSE:PBH Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 975.78 -35.80 228.55
2018-12-31 990.72 63.79 231.01
2018-09-30 1,019.92 340.41 232.67
2018-06-30 1,038.59 340.28 232.79
2018-03-31 1,041.18 339.57 229.48
2017-12-31 1,025.88 390.35 227.21
2017-09-30 972.03 107.20 223.36
2017-06-30 929.06 108.69 209.56
2017-03-31 882.06 69.40 199.27
2016-12-31 849.25 72.24 190.28
2016-09-30 832.68 68.60 185.53
2016-06-30 823.69 68.20 182.50
2016-03-31 806.25 99.91 179.42
2015-12-31 788.44 109.74 165.59
2015-09-30 785.85 103.04 167.12
2015-06-30 761.05 87.70 179.53
2015-03-31 714.62 78.26 167.02
2014-12-31 667.63 70.49 167.37
2014-09-30 614.90 52.33 154.14
2014-06-30 600.57 68.66 133.54
2014-03-31 597.38 72.62 132.35
2013-12-31 608.84 75.96 138.26
2013-09-30 624.20 85.09 135.01
2013-06-30 619.11 71.54 134.94
2013-03-31 620.12 65.51 133.82
2012-12-31 603.08 46.14 128.97
2012-09-30 549.10 43.39 124.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Prestige Consumer Healthcare has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • Prestige Consumer Healthcare used its assets less efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.
  • It is difficult to establish if Prestige Consumer Healthcare improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Prestige Consumer Healthcare's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Prestige Consumer Healthcare has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PBH Health

 How is Prestige Consumer Healthcare's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Prestige Consumer Healthcare's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Prestige Consumer Healthcare is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Prestige Consumer Healthcare's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Prestige Consumer Healthcare's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Prestige Consumer Healthcare Company Filings, last reported 3 months ago.

NYSE:PBH Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 1,095.83 1,798.60 27.53
2018-12-31 1,233.12 1,842.29 24.67
2018-09-30 1,193.24 1,895.84 36.91
2018-06-30 1,161.72 1,993.80 34.27
2018-03-31 1,178.61 1,992.95 32.55
2017-12-31 1,217.44 2,053.27 45.38
2017-09-30 895.97 2,092.09 42.98
2017-06-30 858.55 2,145.41 44.14
2017-03-31 822.55 2,193.73 41.86
2016-12-31 799.86 1,415.58 63.29
2016-09-30 774.64 1,479.66 30.46
2016-06-30 737.48 1,577.41 28.88
2016-03-31 744.34 1,625.31 27.23
2015-12-31 720.94 1,447.03 48.97
2015-09-30 685.76 1,471.86 22.15
2015-06-30 662.72 1,515.07 21.60
2015-03-31 627.62 1,561.27 21.32
2014-12-31 608.94 1,637.96 21.95
2014-09-30 594.04 1,692.31 21.75
2014-06-30 585.81 969.56 15.68
2014-03-31 563.36 934.41 28.33
2013-12-31 543.93 1,029.80 94.35
2013-09-30 541.25 978.70 26.83
2013-06-30 500.31 953.25 19.31
2013-03-31 477.94 970.90 15.67
2012-12-31 457.33 1,000.30 10.43
2012-09-30 438.70 1,079.72 29.01
  • Prestige Consumer Healthcare's level of debt (164.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (165.9% vs 164.1% today).
  • Debt is not well covered by operating cash flow (10.5%, less than 20% of total debt).
  • Prestige Consumer Healthcare is making a loss, therefore interest payments are not well covered by earnings.
X
Financial health checks
We assess Prestige Consumer Healthcare's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Prestige Consumer Healthcare has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PBH Dividends

 What is Prestige Consumer Healthcare's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Prestige Consumer Healthcare dividends.
If you bought $2,000 of Prestige Consumer Healthcare shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Prestige Consumer Healthcare's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Prestige Consumer Healthcare's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NYSE:PBH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2016 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NYSE:PBH Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-03-31
2020-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Prestige Consumer Healthcare has not reported any payouts.
  • Unable to verify if Prestige Consumer Healthcare's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Prestige Consumer Healthcare's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Prestige Consumer Healthcare has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Prestige Consumer Healthcare's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Prestige Consumer Healthcare afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Prestige Consumer Healthcare has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PBH Management

 What is the CEO of Prestige Consumer Healthcare's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ron Lombardi
COMPENSATION $4,274,547
AGE 55
TENURE AS CEO 4.1 years
CEO Bio

Mr. Ronald M. Lombardi, also known as Ron, has been the Chief Executive Officer and President of Prestige Brands Holdings, Inc. (now Prestige Consumer Healthcare Inc.) since June 2015 and has been its Chairman since May 11, 2017. Mr. Lombardi is Chairman of the Board, President & CEO at Prestige Brands Inc. since April 2019. Mr. Lombardi has Leadership Experience, Financial Experience and Consumer Products Experience. He served as the Chief Financial Officer of Prestige Brands Holdings, Inc. from December 6, 2010 to June 1, 2015, Treasurer until June 1, 2015 and served as its Interim Chief Financial Officer since August 5, 2016 until September 12, 2016. Prior to joining Prestige Brands Holdings, from October 2010 to December 2010, Mr. Lombardi was employed by Medtech Group Holdings as Chief Financial Officer. He has extensive financial management experience with expertise in acquisitions and divestitures, debt and equity structuring and building financial infrastructure. He served as Chief Financial Officer for Waterbury International Holdings from October 2009 to October 2010 and was responsible for all financial and business development activities, leading to the successful sale of company. He served at Cannondale Sports Group/Dorel Recreation and Leisure in positions of increasing financial responsibility, including as Senior Vice President and Chief Financial Officer from March 2004 to August 2008 and then as Chief Operating Officer from August 2008 to October 2009. He serves as a Director of Prestige Brands Holdings, Inc. since June 2015. From 2000 to 2004, Mr. Lombardi served in various roles at Gerber Scientific Inc., including Vice President and Chief Financial Officer of Gerber Scientific Inc.’s Gerber Coburn Optical Division and Director of Financial Planning and Analysis of Gerber Scientific Inc. Mr. Lombardi was also previously employed by Emerson Electric, Scovill Fasteners, Inc. and Go/Dan Industries. He has been Director of ACCO Brands Corp. since March 8, 2018. He is a Certified Public Accountant. He was a licensed CPA. Mr. Lombardi holds a B.S. from Springfield College and an MBA from American International College.

CEO Compensation
  • Ron's compensation has increased whilst company is loss making.
  • Ron's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Prestige Consumer Healthcare management team in years:

2.7
Average Tenure
54.5
Average Age
  • The tenure for the Prestige Consumer Healthcare management team is about average.
Management Team

Ron Lombardi

TITLE
Chairman
COMPENSATION
$4M
AGE
55
TENURE
4.1 yrs

Chris Sacco

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
43
TENURE
2.8 yrs

Jeff Zerillo

TITLE
Senior Vice President of Operations
COMPENSATION
$1M
AGE
58
TENURE
1.3 yrs

Bill P'Pool

TITLE
Senior VP
COMPENSATION
$1M
AGE
54
TENURE
2.7 yrs

Phil Terpolilli

TITLE
Director of Investor Relations

Dean Siegal

TITLE
Director of Communications

Mary Fritz

TITLE
Senior Vice President of Quality & Regulatory Affairs
TENURE
1.1 yrs
Board of Directors Tenure

Average tenure and age of the Prestige Consumer Healthcare board of directors in years:

4.2
Average Tenure
70
Average Age
  • The tenure for the Prestige Consumer Healthcare board of directors is about average.
Board of Directors

John Byom

TITLE
Director
COMPENSATION
$228K
AGE
65
TENURE
13.5 yrs

Ron Lombardi

TITLE
Chairman
COMPENSATION
$4M
AGE
55
TENURE
2.2 yrs

Carl Johnson

TITLE
Director
COMPENSATION
$223K
AGE
71
TENURE
5.9 yrs

Jim Jenness

TITLE
Director
COMPENSATION
$225K
AGE
73
TENURE
4.2 yrs

Gary Costley

TITLE
Lead Independent Director
COMPENSATION
$235K
AGE
75
TENURE
9.8 yrs

Sheila Hopkins

TITLE
Director
COMPENSATION
$210K
AGE
63
TENURE
3.9 yrs

Nat Ricciardi

TITLE
Director
COMPENSATION
$210K
AGE
70
TENURE
3.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
20. Nov 18 Sell Timothy Connors Individual 19. Nov 18 19. Nov 18 -34,000 $38.25 $-1,300,500
15. Nov 18 Sell Timothy Connors Individual 13. Nov 18 13. Nov 18 -14,300 $39.00 $-557,700
X
Management checks
We assess Prestige Consumer Healthcare's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Prestige Consumer Healthcare has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PBH News

Simply Wall St News

Read This Before Buying Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares

View our latest analysis for Prestige Consumer Healthcare The Last 12 Months Of Insider Transactions At Prestige Consumer Healthcare In the last twelve months, the biggest single sale by an insider was when the , Timothy Connors, sold US$1.3m worth of shares at a price of US$38.25 per share. … Based on our data, Prestige Consumer Healthcare insiders have about 0.3% of the stock, worth approximately US$4.7m. … So What Do The Prestige Consumer Healthcare Insider Transactions Indicate?

Simply Wall St -

An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 36% Undervalued

Today, we will estimate the stock's intrinsic value by estimating the company's future cash flows and discounting them to their present value. … A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value: 10-year free cash flow (FCF) estimate 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Levered FCF ($, Millions) $187.15 $206.29 $198.78 $195.25 $194.42 $195.44 $197.75 $201.01 $204.98 $209.48 Growth Rate Estimate Source Analyst x2 Analyst x2 Analyst x2 Est @ -1.78% Est @ -0.42% Est @ 0.52% Est @ 1.18% Est @ 1.65% Est @ 1.97% Est @ 2.2% Present Value ($, Millions) Discounted @ 9.51% $170.91 $172.03 $151.38 $135.79 $123.47 $113.34 $104.73 $97.22 $90.53 $84.49 Present Value of 10-year Cash Flow (PVCF)= $1.24b "Est" = FCF growth rate estimated by Simply Wall St The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. … NYSE:PBH Intrinsic value, June 19th 2019 Important assumptions Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows.

Simply Wall St -

How Much Did Prestige Consumer Healthcare Inc.'s (NYSE:PBH) CEO Pocket Last Year?

View our latest analysis for Prestige Consumer Healthcare How Does Ron Lombardi's Compensation Compare With Similar Sized Companies? … The graphic below shows how CEO compensation at Prestige Consumer Healthcare has changed from year to year. … NYSE:PBH CEO Compensation, May 29th 2019 Is Prestige Consumer Healthcare Inc.

Simply Wall St -

Prestige Consumer Healthcare Inc. (NYSE:PBH): What Does Its Beta Value Mean For Your Portfolio?

Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … To use beta as an investor, you must first understand that the overall market has a beta of one. … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

Is Prestige Consumer Healthcare Inc. (NYSE:PBH) A Financially Sound Company?

While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Evaluating financial health as part of your investment thesis is. … Let's work through some financial health checks you may wish to consider if you're interested in this stock.

Simply Wall St -

Is Prestige Consumer Healthcare Inc.'s (NYSE:PBH) 5.2% ROE Worse Than Average?

By way of learning-by-doing, we'll look at ROE to gain a better understanding of Prestige Consumer Healthcare Inc. … Prestige Consumer Healthcare has a ROE of 5.2%, based on the last twelve months. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Have Insiders Been Selling Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares?

So before you buy or sell Prestige Consumer Healthcare Inc. … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … The Last 12 Months Of Insider Transactions At Prestige Consumer Healthcare.

Simply Wall St -

Some Prestige Consumer Healthcare Shareholders Are Down 42%

(NYSE:PBH) shareholders have had that experience, with the share price dropping 42% in three years, versus a market return of about 53%. … While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. … One flawed but reasonable way to assess how sentiment around a company has changed, is to compare the earnings per share (EPS) with the share price.

Simply Wall St -

Before You Buy Prestige Consumer Healthcare Inc. (NYSE:PBH), Consider Its Volatility

Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful. … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

Prestige Consumer Healthcare Inc. (NYSE:PBH) Is Trading At A 36.63% Discount

by taking the expected future cash flows and discounting them to today's value. … discounted cash flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model

Simply Wall St -

PBH Company Info

Description

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids/lozenges, Clear Eyes for eye allergies/redness relief, Compound W wart removals, Debrox ear wax removals, DenTek for PEG oral care, and Dramamine for motion sickness relief. It also provides Fess nasal saline spray, Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Hydralyte for oral rehydration, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Pedia-Lax pediatric laxatives, and Summer's Eve feminine hygiene products. The company mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Details
Name: Prestige Consumer Healthcare Inc.
PBH
Exchange: NYSE
Founded: 1996
$1,643,105,553
51,203,040
Website: http://www.prestigebrands.com
Address: Prestige Consumer Healthcare Inc.
660 White Plains Road,
Suite 250,
Tarrytown,
New York, 10591,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE PBH Common Stock New York Stock Exchange US USD 10. Feb 2005
DB PBV Common Stock Deutsche Boerse AG DE EUR 10. Feb 2005
Number of employees
Current staff
Staff numbers
520
Prestige Consumer Healthcare employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/21 00:07
End of day share price update: 2019/07/19 00:00
Last estimates confirmation: 2019/07/19
Last earnings filing: 2019/05/13
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.